Riset dan Pengabdian Masyarakat
Do Research Sosial Service and Innovation
Publikasi Scopus 2024 per tanggal 30 September 2024 (820 artikel)
Publikasi Scopus 2024 per tanggal 30 September 2024 (820 artikel)
Thanh, Tran Tan (7004531564); Tu, Nguyen Thi Kha (58429284900); Nguyet, Lam Anh (55902545400); Thuy, Cao Thu (35273734000); Thuan, Nguyen Lam Thai (59293573700); Ny, Nguyen Thi Han (56556862600); Nhu, Le Nguyen Truc (15837969100); Thanh, Le Kim (57220088404); Hong, Nguyen Thi Thu (57194593541); Anh, Nguyen To (59293573800); Truong, Nguyen Thanh (59254821200); Chau, Nguyen Van Vinh (23007606000); Yen, Lam Minh (12772247500); Van E, Phan (59294055600); Thuong, Nguyen Phong (59293732000); Van Truc,
Immunogenicity of Abdala COVID-19 vaccine in Vietnamese people after primary and booster vaccinations: A prospective observational study in Vietnam
2024
International Journal of Infectious Diseases
147
107173
0
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85201784428&doi=10.1016%2fj.ijid.2024.107173&partnerID=40&md5=373cdc4b42c7679c1b66f0d87b301559
Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam; Center for Disease Control, Dong Thap Province, Viet Nam; Department of Health, Dong Thap Province, Viet Nam; Tan Phu Hospital, Ho Chi Minh City, Viet Nam; Department of Health, Ho Chi Minh City, Viet Nam; Health Center, Thanh Binh District, Dong Thap Province, Viet Nam; Health Center, Thap Muoi District, Dong Thap Province, Viet Nam; Commune Health Station, My Qui Commune, Thap Muoi District, Dong Thap Province, Viet Nam; Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Diagnostics Development Hub, Agency for Science, Technology and Research (A*STAR), Singapore; Centre of Regulatory Excellence, Duke-NUS Medical School, Singapore; Department of Obstetrics and Gynaecology, NUS YLL School of Medicine, Singapore; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Division of Emerging Infectious Disease, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Oxford University Clinical Research Unit, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam; Programme for Emerging Infectious Diseases, Duke-NUS Medical School, Singapore
Objectives: We studied the immunogenicity after primary and booster vaccinations of the Abdala COVID-19 vaccine, a receptor-binding domain protein subunit vaccine, in Vietnamese people by determining the level of neutralization and cross-neutralization activities against the ancestral SARS-CoV-2 and its variants and SARS-CoV-1. Methods: We performed a prospective observational study, enrolling adults aged 19-59 years in Dong Thap province, southern Vietnam, and collected blood samples from baseline until 4 weeks after the booster dose. We measured anti-nucleocapsid, anti-spike, and neutralizing antibodies against SARS-CoV-2 and assessed the cross-neutralization against 14 SARS-CoV-2 variants and SARS-CoV-1. Complementary antibody data came from Vietnamese health care workers fully vaccinated with ChAdOx1-S. Results: After primary vaccination, anti-spike antibody and neutralizing antibodies were detectable in 98.4% and 87% of 251 study participants, respectively, with neutralizing antibody titers similar to that induced by ChAdOx1-S vaccine. Antibody responses after a homologous (Abdala COVID-19) or heterologous (messenger RNA BNT162b2) booster could neutralize 14 SARS-CoV-2 variants (including Omicron) and SARS-CoV-1. Conclusions: Abdala COVID-19 vaccine is immunogenic in Vietnamese people. Enhanced antibody response after a booster dose could cross-neutralize 14 SARS-CoV-2 variants and SARS-CoV-1. Our results have added to the growing body of knowledge about the contribution of protein subunit vaccine platforms to pandemic control. © 2024 The Author(s)
chadox 1s; neutralizing antibody; subunit vaccine; vaxzevria; adult; antibody response; Article; blood sampling; breakthrough infection; comparative study; controlled study; coronavirus disease 2019; demographics; female; health care personnel; human; major clinical study; male; observational study; prospective study; receptor binding; respiratory tract disease; reverse transcription polymerase chain reaction; seroconversion; vaccination; vaccine immunogenicity; Viet Nam
Dalian Science and Technology Innovation Fund; 8Siriraj Center of Research Excellence in Dengue and Emerging Pathogens, Faculty of Medicine Siriraj Hospital, Mahidol University; Mahidol University, MU; Nippon Telegraph and Telephone, NTT; Trinh Son Tung2; National University of Singapore, NUS; NLTT; Anak Agung Sagung Sawitri7; 4Programme for Emerging Infectious Diseases; Duke-NUS Medical School; Temasek Foundation, Singapore; NTD; 6Wellcome Centre for Human Genetics, Nuffield Department of Medic
Funding text 1: This work was supported in part by Temasek Foundation, Singapore, ASEAN Science Technology and Innovation Fund, Roche Diagnostics, GenScript and the Wellcome Trust, United Kingdom [ 226120/Z/22/Z , 222574/Z/21/Z and 225437/Z/22/Z ]. The funding bodies did not have any influence on the study design, study conduct, preparation of the manuscript or decision to publish. ; Funding text
Elsevier B.V.
12019712
39094762
Article
Q1
1435
2434